The links between complex coronary disease, cerebrovascular disease, and degenerative brain disease

Annals of the New York Academy of Sciences

Volumn 1254, Issue 1, 2012, Pages 99-105

  Kovacic, Jason C ^a   Castellano, Jose M ^a   Fuster, Valentin ^a,b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

SIRTUIN 1;

ARTICLE; CARDIOVASCULAR RISK; CAROTID ARTERY OBSTRUCTION; CAROTID ARTERY STENTING; CAROTID ENDARTERECTOMY; CEREBROVASCULAR DISEASE; COMPLEX CORONARY ARTERY DISEASE; CORONARY ARTERY DISEASE; DEGENERATIVE DISEASE; HUMAN; HYPERTENSION;

EID: 84860445434     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2012.06482.x     Document Type: Article

References (55)

1. Kovacic, J.C. et al 2011. From treating complex coronary artery disease to promoting cardiovascular health: therapeutic transitions and challenges, 2010-2020. Clin. Pharmacol. Ther. 90: 509-518.
2. Borden, W.B. et al 2011. Patterns and intensity of medical therapy in patients undergoing percutaneous coronary intervention. JAMA 305: 1882-1889.
3. Kovacic, J.C. et al 2006. Staged carotid artery stenting and coronary artery bypass graft surgery: initial results from a single center. Catheter Cardiovasc. Interv. 67: 142-148.
4. Steinvil, A. et al 2011. Prevalence and predictors of concomitant carotid and coronary artery atherosclerotic disease. J. Am. Coll. Cardiol. 57: 779-783.
5. Park, H.W. et al 2012. Carotid plaque is associated with increased cardiac mortality in patients with coronary artery disease. Int. J. Cardiol. In press.
6. Brott, T.G. et al 2011. ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines, and the American Stroke Association, American Association of Neuroscience Nurses, American Association of Neurological Surgeons, American College of Radiology, American Society of Neuroradiology, Congress of Neurological Surgeons, Society of Atherosclerosis Imaging and Prevention, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of NeuroInterventional Surgery, Society for Vascular Medicine, and Society for Vascular Surgery. Stroke 42: e420-e463.
7. Kovacic, J.C. et al 2005. Percutaneous carotid artery stenting: a strategy in evolution. Intern. Med. J. 35: 143-150.
8. Venkatachalam, S. et al 2011. Management of carotid disease in patients undergoing coronary artery bypass surgery: is it time to change our approach? Curr. Opin. Cardiol. 26: 480-487.
9. Corti, R. et al 2011. Imaging of atherosclerosis: magnetic resonance imaging. Eur. Heart J. 32: 1709b-1719b.
10. Muntendam, P. et al 2010. The BioImage Study: novel approaches to risk assessment in the primary prevention of atherosclerotic cardiovascular disease-study design and objectives. Am. Heart J. 160: 49-57 e1.
11. Kovacic, J.C. et al 2011. Cellular senescence, vascular disease, and aging: part 2 of a 2-part review: clinical vascular disease in the elderly. Circulation 123: 1900-1910.
12. Ferri, C.P. et al 2005. Global prevalence of dementia: a Delphi consensus study. Lancet 366: 2112-2117.
13. 2011. The three stages of Alzheimer's disease. Lancet 377: 1465.
14. Chandra, V. et al 1998. Gene-environment interaction in Alzheimer's disease: a potential role for cholesterol. Neuroepidemiology 17: 225-232.
15. Kivipelto, M. et al 2001. Midlife vascular risk factors and late-life mild cognitive impairment: a population-based study. Neurology 56: 1683-89.
16. Larson, E.B. et al 2006. Exercise is associated with reduced risk for incident dementia among persons 65 years of age and older. Ann. Intern. Med. 144: 73-81.
17. Kennelly, S.P. et al 2009. Blood pressure and the risk for dementia: a double edged sword. Ageing Res. Rev. 8: 61-70.
18. Luchsinger, J.A. et al 2009. Adiposity and Alzheimer's disease. Curr. Opin. Clin. Nutr. Metab. Care 12: 15-21.
19. Ott, A. et al 1999. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology 53: 1937-1942.
20. Ott, A. et al 1998. Smoking and risk of dementia and Alzheimer's disease in a population-based cohort study: the Rotterdam Study. Lancet 351: 1840-1843.
21. Maouche, S. et al 2012. Strategies beyond genome-wide association studies for atherosclerosis. Arterioscler Thromb. Vasc. Biol. 32: 170-181.
22. Helgadottir, A. et al 2007. A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science 316: 1491-1493.
23. Wahlstrand, B. et al 2009. The myocardial infarction associated CDKN2A/CDKN2B locus on chromosome 9p21 is associated with stroke independently of coronary events in patients with hypertension. J. Hypertens. 27: 769-773.
24. Zuchner, S. et al 2008. Linkage and association study of late-onset Alzheimer disease families linked to 9p21.3. Ann. Hum. Genet. 72: 725-731.
25. Emanuele, E. et al 2011. Chromosome 9p21.3 genotype is associated with vascular dementia and Alzheimer's disease. Neurobiol. Aging 32: 1231-1235.
26. Farkas, E. et al 2001. Cerebral microvascular pathology in aging and Alzheimer's disease. Prog. Neurobiol. 64: 575-611.
27. Iadecola, C. et al 2009. Threats to the mind: aging, amyloid, and hypertension. Stroke 40: S40-S44.
28. Kawai, M. et al 1993. Degeneration of vascular muscle cells in cerebral amyloid angiopathy of Alzheimer disease. Brain Res. 623: 142-46.
29. Thompson, C.S. et al 2009. Living beyond our physiological means: small vessel disease of the brain is an expression of a systemic failure in arteriolar function: a unifying hypothesis. Stroke 40: e322-e330.
30. Herzig, M.C. et al 2004. Abeta is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis. Nat. Neurosci. 7: 954-960.
31. Bell, R.D. et al 2009. Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease. Acta Neuropathol. 118: 103-113.
32. Itoh, Y. et al 1993. Cerebral amyloid angiopathy: a significant cause of cerebellar as well as lobar cerebral hemorrhage in the elderly. J. Neurol. Sci. 116: 135-41.
33. Pettersen, J.A. et al 2008. Microbleed topography, leukoaraiosis, and cognition in probable Alzheimer disease from the Sunnybrook dementia study. Arch. Neurol. 65: 790-5.
34. Russell, J.W. et al 1999. Neurons undergo apoptosis in animal and cell culture models of diabetes. Neurobiol. Dis. 6: 347-363.
35. Auer, R.N. et al 1984. The distribution of hypoglycemic brain damage. Acta Neuropathol. 64: 177-191.
36. Kramer, L. et al 1998. Previous episodes of hypoglycemic coma are not associated with permanent cognitive brain dysfunction in IDDM patients on intensive insulin treatment. Diabetes 47: 1909-14.
37. Ho, L. et al 2004. Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. Faseb J. 18: 902-904.
38. Kearney, P.M. et al 2005. Global burden of hypertension: analysis of worldwide data. Lancet 365: 217-223.
39. Novak, V. et al 2010. The relationship between blood pressure and cognitive function. Nat. Rev. Cardiol. 7: 686-698.
40. Hajjar, I. et al 2011. Hypertension, white matter hyperintensities, and concurrent impairments in mobility, cognition, and mood: the Cardiovascular Health Study. Circulation 123: 858-65.
41. White, W.B. et al 2011. Average daily blood pressure, not office blood pressure, is associated with progression of cerebrovascular disease and cognitive decline in older people. Circulation 124: 2312-2319.
42. Kovacic, J.C. et al 2011. Cellular senescence, vascular disease, and aging: part 1 of a 2-part review. Circulation 123: 1650-1660.
43. Donmez, G. et al 2010. SIRT1 suppresses beta-amyloid production by activating the alpha-secretase gene ADAM10. Cell 142: 320-332.
44. Kim, D. et al 2007. SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis. Embo. J. 26: 3169-79.
45. Huang, T.C. et al 2011. Resveratrol protects rats from abeta-induced neurotoxicity by the reduction of iNOS expression and lipid peroxidation. PLoS One 6: e29102.
46. Launer, L.J. et al 2010. Lowering midlife levels of systolic blood pressure as a public health strategy to reduce late-life dementia: perspective from the Honolulu Heart Program/Honolulu Asia Aging Study. Hypertension 55: 1352-1359.
47. Boden, W.E. et al 2007. Optimal medical therapy with or without PCI for stable coronary disease. N. Engl. J. Med. 356: 1503-1516.
48. Frye, R.L. et al 2009. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N. Engl. J. Med. 360: 2503-2515.
49. Serruys, P.W. et al 2009. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N. Engl. J. Med. 360: 961-972.
50. Serruys, P.W. et al 2009. Assessment of the SYNTAX score in the SYNTAX study. EuroIntervention 5: 50-56.
51. Sianos, G. et al 2005. The SYNTAX score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention 1: 219-227.
52. Garg, S. et al 2010. A new tool for the risk stratification of patients with complex coronary artery disease: the Clinical SYNTAX score. Circ. Cardiovasc. Interv. 3: 317-326.
53. Tonino, P.A. et al 2009. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N. Engl. J. Med. 360: 213-224.
54. Farkouh, M.E. et al 2008. Design of the Future REvascularization Evaluation in patients with Diabetes mellitus: Optimal management of Multivessel disease (FREEDOM) Trial. Am. Heart J. 155: 215-223.
55. Stone, G.W. et al 2011. A prospective natural-history study of coronary atherosclerosis. N. Engl. J. Med. 364: 226-35.